Compare ACDC & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACDC | CDNA |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 703.6M | 712.2M |
| IPO Year | 2022 | 2014 |
| Metric | ACDC | CDNA |
|---|---|---|
| Price | $3.91 | $19.32 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $5.83 | ★ $26.67 |
| AVG Volume (30 Days) | ★ 1.3M | 841.8K |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.22 |
| Revenue | ★ $1,960,000,000.00 | $357,998,000.00 |
| Revenue This Year | N/A | $14.11 |
| Revenue Next Year | N/A | $12.00 |
| P/E Ratio | ★ N/A | $16.01 |
| Revenue Growth | N/A | ★ 14.46 |
| 52 Week Low | $3.08 | $10.96 |
| 52 Week High | $10.70 | $25.95 |
| Indicator | ACDC | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 44.61 | 60.43 |
| Support Level | $3.78 | $19.21 |
| Resistance Level | $4.64 | $20.05 |
| Average True Range (ATR) | 0.28 | 0.89 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 22.31 | 61.97 |
ProFrac Holding Corp is engaged in providing hydraulic fracturing, completion services, and other complementary products and services to upstream oil and gas companies engaged in the exploration and production of North American unconventional oil and natural gas resources. The company operates in three segments: Stimulation Services, Proppant Production, and Manufacturing. Stimulation services, which generate the majority of the revenue for the company operate a fleet of mobile hydraulic fracturing units and other auxiliary equipment that generates revenue by providing stimulation services.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.